| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12603-009-0036-7 |
| P698 | PubMed publication ID | 19300873 |
| P2093 | author name string | E R Siemers | |
| P2860 | cites work | Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families | Q27860677 |
| The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 | ||
| Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease | Q29614952 | ||
| The role of biomarkers in clinical trials for Alzheimer disease | Q31032781 | ||
| Imaging-based measures of disease progression in clinical trials of disease-modifying drugs for Alzheimer disease | Q33186215 | ||
| Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. | Q34417339 | ||
| Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease | Q35114490 | ||
| Alzheimer disease: mechanistic understanding predicts novel therapies | Q35750804 | ||
| Frequent amyloid deposition without significant cognitive impairment among the elderly | Q37085957 | ||
| Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease | Q37192883 | ||
| Optimal design of clinical trials for drugs designed to slow the course of Alzheimer's disease | Q37549247 | ||
| The NINCDS-ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease: a clinicopathologic study of 57 cases | Q39104464 | ||
| Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers | Q46555308 | ||
| Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase | Q46843030 | ||
| Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease | Q46966608 | ||
| Two-year follow-up of amyloid deposition in patients with Alzheimer's disease | Q48467767 | ||
| Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. | Q48893777 | ||
| Commentary on "a roadmap for the prevention of dementia: the inaugural Leon Thal Symposium". | Q49075598 | ||
| Longitudinal stability of CSF tau levels in Alzheimer patients. | Q51981435 | ||
| Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. | Q51983988 | ||
| Longitudinal stability of CSF biomarkers in Alzheimer's disease. | Q53286684 | ||
| Are surrogate markers adequate to assess cardiovascular disease drugs? | Q78175808 | ||
| P433 | issue | 4 | |
| P304 | page(s) | 341-343 | |
| P577 | publication date | 2009-04-01 | |
| P1433 | published in | The Journal of Nutrition, Health and Aging | Q23051112 |
| P1476 | title | How can we recognize "disease modification" effects? | |
| P478 | volume | 13 |
| Q37730012 | Biochemical markers in Alzheimer's disease clinical trials |
| Q37769104 | Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives |
| Q39432592 | Cerebrospinal Fluid Biomarkers in Alzheimer's Disease-From Brain Starch to Bench and Bedside |
| Q34098866 | Cerebrospinal fluid and plasma biomarkers in Alzheimer disease |
| Q87388529 | Effects of single doses of avagacestat (BMS-708163) on cerebrospinal fluid Aβ levels in healthy young men |
| Q26784569 | Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics |
| Q36186513 | Fluid biomarkers in Alzheimer disease |
| Q53300553 | Imaging and biomarkers will be used for detection and monitoring progression of early Alzheimer's disease. |
| Q38113683 | Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid |
| Q26866006 | New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs |
| Q41683709 | The retina as an early biomarker of neurodegeneration in a rotenone-induced model of Parkinson's disease: evidence for a neuroprotective effect of rosiglitazone in the eye and brain |
| Q53300550 | Use of biomarkers in Alzheimer's trials. |
| Q37814497 | Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease |
| Q35533115 | Using biomarkers to improve detection of Alzheimer's disease. |
Search more.